Hemispherian AS is a biotechnology firm that formulates new treatments for all kinds of cancer.In November 2022, Hemispherian AS announced the closure of the first tranche of its series A1 financing round raising NOK 30M led Meneldor.In May 2022, Hemispherian AS closed its oversubscribed seed financing round and raised NOK 12.5M.In October 2022, Hemispherian AS announced a successful European Commission Accelerator grant application. This grant will provide EUR 2.5M in grant funding, and the jury recommends an additional EUR 7.5M in equity financing from the EIC fund. Financing from the EIC accelerator will be used to advance GLIX1, one of Hemispherian's lead assets, through a phase I and phase II clinical trial